INTRODUCTION
7 food equal to the least amount consumed by the mice on the previous day. Before fasting, all 136 mice were given free access to food, and food intake of each mouse was measured. Every 7 137 days after the feeding initiation, blood samples were collected from the tail vein to measure 138 serum glucose level, and glucosuria incidence was estimated using Uropiece S (Fujisawa 139 Pharmaceutical, Osaka). Three to four weeks after feeding, an oral glucose tolerance test was 140 carried out by administering D-glucose (2 g/kg body weight) through a gastric feeding tube 141 after fasting overnight. For the insulin tolerance test, human insulin (Eli Lilly Japan, Kobe, 142 Japan) was injected intraperitoneally (0.6 units/kg body weight) in non-fasted animals. Blood 143 samples were collected from the tail vein before and 30, 60, 90 and 120 min after injection.
144
Area under the curve (AUC) was calculated using the trapezoidal rule. Five weeks after 145 feeding, mice were fasted 1 hour before harvesting blood for metabolic characteristic analysis, 146 and tissues for RNA isolation, lipid measurements, and histochemistry. Serum glucose, TG, determined enzymatically using the Wako triglyceride G-test.
165
The liver was removed from each animal, and then fixed in 10% formaldehyde/PBS.
166
The fixed samples were embedded in the optimal cutting temperature (OCT) compound in 167 isopentane cooled with liquid nitrogen. They were cut into 8 µm sections using a cryostat at 168 -30°C and placed on microscope slides (Matsunami glass, Osaka, Japan). Liver cryosections 169 were fixed in 50% ethanol for a few minutes and stained with 2% Sudan III in 70% ethanol expression levels were represented as the ratio relative to that of a control in each experiment.
206
Preparation of mouse primary hepatocytes.
207
Primary hepatocytes were prepared from 10-week-old male mice as previously 208 described with slight modifications (52). In the light phase, animals were anesthetized with 209 pentobarbital and livers were perfused with 40 ml of liver perfusion medium (Invitrogen, CA,
210
USA) followed by 30 ml of liver digestion medium (Invitrogen), both at a flow rate of 5 211 ml/min at 37 °C. Liver cells were dispersed in Williams' E medium (Sigma) by dissection and 212 gentle shaking. After filtration through a 100 μm nylon mesh filter, hepatocytes were isolated 213 by repeated centrifugation (4 times) at 50g for 2 min. Isolated hepatocytes were suspended in
214
Williams' E medium supplemented with 10% FBS, 0.1 μM insulin, 1 μM dexamethasone, 100
215
U/ml penicillin, and 100 μg/ml streptomycin, and seeded at a density of 2. Statistical analyse.
249
The data, presented as means ± SEM, were statistically analyzed using ANOVA and high-density lipoprotein (HDL) (Supplemental Table 2 ). These findings demonstrate that in a dose-dependent manner (Fig. 3D-F Fig. 7A and B) . In the assay, and FAS (63 and 13%, respectively) at a concentration of 100 μM farnesol (Fig. 7D ). In the
369
PPARα (-/-) hepatocytes, similar changes were observed (1.7-fold increase in SHP mRNA 370 expression level and 36% and 33% decreases in SREBP-1c and FAS mRNA expression levels, 371 respectively) (Fig. 7D) . Furthermore, in the presence of the FXR antagonist, guggulsterone, 372 the extent to which farnesol induced a decrease in TG synthesis was attenuated (Fig. 7E) . PPARα stimulation by farnesol was not strong enough to produce hepatomegaly. In our ACO, CPT1, and UCP2, respectively, in mice fed a 0.5% FOH diet; Fig. 3 ).
439
In contrast to the differences in PPARγ target gene expression and serum TG levels, 
464
Further study may be necessary to clarify the detail mechanisms. is unclear, but it is possible that the differences may be due to the use of different cell types.
481
Duncan et al. used Clone-9 rat hepatocytes, whereas we used primary mouse hepatocytes (8).
482
In addition, they have reported that farnesol does not alter SREBP-1c expression at the 483 concentration of 30 μM (8). In the present study, we were not able to detect the decrease in PPARα and FXR, especially in whole animal system, has never been studied. To our 
505
In summary, we reported here the effects of dietary farnesol on carbohydrate and lipid 506 metabolisms. Dietary farnesol prevented HFD-induced hyperglycemia and hepatic steatosis.
507
The dual activation of PPARα and FXR by farnesol seems to be involved in these effects.
508
Dietary patterns rich in vegetables and fruit are associated with a lower prevalence of 509 metabolic syndrome (12). Because farnesol is contained in vegetables and fruit, the present 510 study suggests that farnesol may contribute to decreasing the risk of metabolic syndrome. 
